Fulcrum Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview

Fulcrum Therapeutics

03/11/2023 18:20

* Fulcrum Therapeutics Inc  FULC.OQ   FULC.O  is expected
to show
a fall in quarterly revenue when it reports  results 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 11.0% decrease in revenue to $1.052 million from $1.18
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Fulcrum
Therapeutics Inc
is for a loss of 43 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fulcrum
Therapeutics Inc is $11​, above​ its last closing price
of $3.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.45       -0.44      -0.38     Beat    14.5
 Mar. 31 2023  -0.47       -0.46      -0.41     Beat    10
 Dec. 31 2022  -0.51       -0.49      -0.50     Missed  -2.1​
 Sep. 30 2022  -0.62       -0.61      -0.51     Beat    16.7
 ​​Jun.        -0.66       -0.66      -0.83     Missed  -25.6
 30 2022                                                
 Mar. 31 2022  -0.62       -0.63      -0.64     Missed  -2.1​
 Dec. 31 2021  -0.71       -0.73      -0.58     Beat    20.3
 Sep. 30 2021  -0.62       -0.65      -0.57     Beat    11.9
 This summary was machine generated November 3 at 18:20 GMT.  All
figures in US dollars  unless otherwise stated